FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385880749> ?p ?o ?g. }

• W4385880749 endingPage "106954" @default.
• W4385880749 startingPage "106954" @default.
• W4385880749 abstract "This study compared clinical outcomes in patients with acute myelogenous leukaemia (AML) who developed prolonged (≥4 days) febrile neutropenia (FN) and received either empirical or pre-emptive antimould prophylaxis in order to evaluate the need for routine empirical antifungal therapy.This retrospective study reviewed adult patients (aged ≥18 years) with AML who developed prolonged FN and received antimould prophylaxis during induction or re-induction chemotherapy at a single centre between September 2016 and December 2020. Patients were categorized into pre-emptive or empirical groups based on whether or not there was clinical evidence of invasive fungal infection (IFI) at the start of antifungal treatment, respectively. Clinical outcomes were compared between the two groups after propensity score matching (PSM).In total, 229 chemotherapy episodes (36 and 193 in the empirical and pre-emptive groups, respectively) were analysed. In the pre-emptive group, broad-spectrum antifungal therapy was administered in 45 (23.3%) episodes. After 1:3 PSM, there were no significant differences between the empirical and pre-emptive groups in terms of the incidence of proven or probable IFI [0/36 (0%) vs 5/97 (5.2%); P=0.323], all-cause mortality [3/36 (8.3%) vs 4/97 (4.1%); P=0.388] and IFI-related mortality [0/36 (0.0%) vs 1/45 (2.2%); P=0.556].The differences in clinical outcomes between empirical and pre-emptive antifungal therapy in patients with AML who received antimould prophylaxis were not significant. Therefore, broad-spectrum antifungal therapy in patients receiving antimould prophylaxis may be delayed until there is clear evidence of IFI." @default.
• W4385880749 created "2023-08-17" @default.
• W4385880749 creator A5010875676 @default.
• W4385880749 creator A5011687418 @default.
• W4385880749 creator A5016807045 @default.
• W4385880749 creator A5020752576 @default.
• W4385880749 creator A5024467564 @default.
• W4385880749 creator A5024828401 @default.
• W4385880749 creator A5028987743 @default.
• W4385880749 creator A5029062187 @default.
• W4385880749 creator A5042580585 @default.
• W4385880749 creator A5048253912 @default.
• W4385880749 creator A5063884420 @default.
• W4385880749 creator A5067482196 @default.
• W4385880749 creator A5076271673 @default.
• W4385880749 date "2023-10-01" @default.
• W4385880749 modified "2023-10-04" @default.
• W4385880749 title "Empirical vs pre-emptive broad-spectrum antifungal therapy for acute myelogenous leukaemia in the era of antimould prophylaxis" @default.
• W4385880749 cites W1989345554 @default.
• W4385880749 cites W2000445173 @default.
• W4385880749 cites W2040113464 @default.
• W4385880749 cites W2053528346 @default.
• W4385880749 cites W2101527023 @default.
• W4385880749 cites W2123859227 @default.
• W4385880749 cites W2132986533 @default.
• W4385880749 cites W2140396674 @default.
• W4385880749 cites W2152583091 @default.
• W4385880749 cites W2154085372 @default.
• W4385880749 cites W2166734004 @default.
• W4385880749 cites W2280404143 @default.
• W4385880749 cites W2326799365 @default.
• W4385880749 cites W2756769237 @default.
• W4385880749 cites W2883043285 @default.
• W4385880749 cites W2887722671 @default.
• W4385880749 cites W2951736308 @default.
• W4385880749 cites W2992250822 @default.
• W4385880749 cites W3214238998 @default.
• W4385880749 doi "https://doi.org/10.1016/j.ijantimicag.2023.106954" @default.
• W4385880749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37595849" @default.
• W4385880749 hasPublicationYear "2023" @default.
• W4385880749 type Work @default.
• W4385880749 citedByCount "0" @default.
• W4385880749 crossrefType "journal-article" @default.
• W4385880749 hasAuthorship W4385880749A5010875676 @default.
• W4385880749 hasAuthorship W4385880749A5011687418 @default.
• W4385880749 hasAuthorship W4385880749A5016807045 @default.
• W4385880749 hasAuthorship W4385880749A5020752576 @default.
• W4385880749 hasAuthorship W4385880749A5024467564 @default.
• W4385880749 hasAuthorship W4385880749A5024828401 @default.
• W4385880749 hasAuthorship W4385880749A5028987743 @default.
• W4385880749 hasAuthorship W4385880749A5029062187 @default.
• W4385880749 hasAuthorship W4385880749A5042580585 @default.
• W4385880749 hasAuthorship W4385880749A5048253912 @default.
• W4385880749 hasAuthorship W4385880749A5063884420 @default.
• W4385880749 hasAuthorship W4385880749A5067482196 @default.
• W4385880749 hasAuthorship W4385880749A5076271673 @default.
• W4385880749 hasBestOaLocation W43858807491 @default.
• W4385880749 hasConcept C120665830 @default.
• W4385880749 hasConcept C121332964 @default.
• W4385880749 hasConcept C126322002 @default.
• W4385880749 hasConcept C141071460 @default.
• W4385880749 hasConcept C16005928 @default.
• W4385880749 hasConcept C167135981 @default.
• W4385880749 hasConcept C17923572 @default.
• W4385880749 hasConcept C185592680 @default.
• W4385880749 hasConcept C21951064 @default.
• W4385880749 hasConcept C2776694085 @default.
• W4385880749 hasConcept C2777063308 @default.
• W4385880749 hasConcept C2778850193 @default.
• W4385880749 hasConcept C2779548794 @default.
• W4385880749 hasConcept C3020442560 @default.
• W4385880749 hasConcept C61511704 @default.
• W4385880749 hasConcept C71924100 @default.
• W4385880749 hasConceptScore W4385880749C120665830 @default.
• W4385880749 hasConceptScore W4385880749C121332964 @default.
• W4385880749 hasConceptScore W4385880749C126322002 @default.
• W4385880749 hasConceptScore W4385880749C141071460 @default.
• W4385880749 hasConceptScore W4385880749C16005928 @default.
• W4385880749 hasConceptScore W4385880749C167135981 @default.
• W4385880749 hasConceptScore W4385880749C17923572 @default.
• W4385880749 hasConceptScore W4385880749C185592680 @default.
• W4385880749 hasConceptScore W4385880749C21951064 @default.
• W4385880749 hasConceptScore W4385880749C2776694085 @default.
• W4385880749 hasConceptScore W4385880749C2777063308 @default.
• W4385880749 hasConceptScore W4385880749C2778850193 @default.
• W4385880749 hasConceptScore W4385880749C2779548794 @default.
• W4385880749 hasConceptScore W4385880749C3020442560 @default.
• W4385880749 hasConceptScore W4385880749C61511704 @default.
• W4385880749 hasConceptScore W4385880749C71924100 @default.
• W4385880749 hasFunder F4320322557 @default.
• W4385880749 hasIssue "4" @default.
• W4385880749 hasLocation W43858807491 @default.
• W4385880749 hasLocation W43858807492 @default.
• W4385880749 hasOpenAccess W4385880749 @default.
• W4385880749 hasPrimaryLocation W43858807491 @default.
• W4385880749 hasRelatedWork W1196768483 @default.
• W4385880749 hasRelatedWork W136411592 @default.
• W4385880749 hasRelatedWork W1990697416 @default.

• next